The Fund supports networks of state health policy decision makers to help identify, inspire, and inform policy leaders.
A bipartisan group of state health policymakers from both the executive and legislative branches who are focused on improving population health.
Networks of state officials, advocates, and others aiming to invest in and transform primary care.
A program dedicated to advancing state-based efforts to make health care more affordable for residents, employers, and states.
The Milbank Memorial Fund supports two state leadership programs for legislative and executive branch state government officials committed to improving population health.
A leadership development program for early and mid-career state government officials who are committed to improving the health of all people in their communities.
A leadership program for senior state government officials who are committed to improving population health.
The Fund focuses on creating an affordable health care system built on strong primary care and partnerships that improve health outcomes for all.
Improving state leaders’ ability to enact and implement evidence-based health policies.
Advancing policies that create a more prevention- and primary care-oriented health system.
Improving population health through policies that contain health care cost growth.
Our state health policy resources offer relevant data analysis and best practices.
The Fund publishes reports, issues briefs, and case studies on state health policy issues.
Short takes on health policy issues from Milbank staff and guest authors.
Insights from Milbank President Debra Lubar on state health policymaking.
Reported articles and Q&As on timely health policy issues, as well as foundation updates.
Milbank Memorial Fund and Milbank Quarterly webinars featuring state health policymakers and researchers.
Updates and expert contact information for reporters.
The Milbank Memorial Fund is a private foundation that works to improve population health and health equity.
As custodians of public funds, state leaders have to determine what to do about high-cost specialty drugs, such as Sovaldi, the expensive and controversial treatment for Hepatitis C. As state officials know only too well, the use of a high-priced drug like Sovaldi could result in an unplanned bottom line increase to already burdened state Medicaid budgets. What should state officials consider when making coverage decisions? What should be the pricing and coverage policies for other high-cost specialty drugs forecasted for release in the coming years?
The MMF has taken on this topic, in response to state interest and questions about high-cost breakthrough drugs. In 2014, the MMF hosted a meeting that enabled researchers and advocates to compare notes about Sovaldi. Also from 2014, read more from Christopher Koller, President of the MMF, about the states and Sovaldi and watch a video on Bio-Pharma Innovations/High Cost Drugs from the Brookings Institute Panel.